Barclays raised the firm’s price target on NiSource (NI) to $44 from $42 and keeps an Overweight rating on the shares as part of a Q2 preview. The firm believes the company has made positive steps in the GenCo regulatory process. NiSource is well positioned for contracting upside in Q3, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NI: